Cationic antimicrobial peptide ll-37 is effective against both extraand intracellular staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 3, 2013, Pages 1283-1290

  Noore, Jabeen ^a   Noore, Adly ^a,b   Li, Bingyun ^a,b,c  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c WVNano Initiative   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; DOXYCYCLINE; LACTOFERRICIN B; POLYPEPTIDE ANTIBIOTIC AGENT;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONCENTRATION (PARAMETERS); DRUG POTENCY; HUMAN; INFECTION; INTRACELLULAR BACTERIUM; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; RECURRENT INFECTION; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; CATHELICIDINS; CEFAZOLIN; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; KINETICS; LACTOFERRIN; MICROBIAL SENSITIVITY TESTS; OSTEOBLASTS; RATS; STAPHYLOCOCCUS AUREUS;

EID: 84874104396     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01650-12     Document Type: Article

References (83)

1. Arias CA, Murray BE. 2009. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. N. Engl. J. Med. 360:439-443.
2. Chambers HF. 2005. Community-associated MRSA-resistance and virulence converge. N. Engl. J. Med. 352:1485-1487.
3. Linares J. 2001. The VISA/GISA problem: therapeutic implications. Clin. Microbiol. Infect. 7:8 -15.
4. Young LS, Perdreau-Remington F, Winston LG. 2004. Clinical, epidemiologic, and molecular evaluation of a clonal outbreak of methicillin resistant Staphylococcus aureus infection. Clin. Infect. Dis. 38:1075-1083.
5. Boucher HW, Corey GR. 2008. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 46:5344 -5349.
6. Jensen AG, Wachmann CH, Espersen F, Scheibel J, Skinhoj P, Frimodt- Moller N. 2002. Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. Arch. Intern. Med. 162:25-32.
7. Martínez-Aguilar G, Avalos-Mishaan A, Hulten K, Hammerman W, Mason EO Jr, Kaplan SL. 2004. Community-acquired, methicillinresistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr. Infect. Dis. J. 23:701-706.
8. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771.
9. CDC. 2009. Rise in life-threatening bacterial infections linked to H1N1 swine flu. http://www.webmd.com/cold-and-flu/news/20091125/worrisome-spike -in-bacterial-infections-with-h1n1-flu. Accession date, 16 February 2012.
10. Chang FY, Peacock JE Jr, Musher DM, Triplett P, MacDonald BB, Mylotte JM, O'Donnell A, Wagener MM, Yu VL. 2003. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine 82:333-339.
11. Johnson LB, Almoujahed MO, Ilg K, Maolood L, Khatib R. 2003. Staphylococcus aureus bacteremia: compliance with standard treatment, long-term outcome and predictors of relapse. Scand. J. Infect. Dis. 35:782- 789.
12. Ciampolini J, Harding KG. 2000. Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often? Postgrad. Med. J. 76:479- 483.
13. Garzoni C, Kelley WL. 2009. Staphylococcus aureus: new evidence for intracellular persistence. Trends Microbiol. 17:59-65.
14. Sendi P, Rohrbach M, Graber P, Frei R, Ochsner PE, Zimmerli W. 2006. Staphylococcus aureus small colony variants in prosthetic joint infection. Clin. Infect. Dis. 43:961-966.
15. Murray CK, Obremskey WT, Hsu JR, Andersen RC, Calhoun JH, Clasper JC, Whitman TJ, Curry TK, Fleming ME, Wenke JC, Ficke JR. 2011. Prevention of Combat-Related Infections Guidelines Panel. Prevention of infections associated with combat-related extremity injuries. J. Trauma 71(Suppl 2):235-257.
16. Bucki R, Leszczyńska K, Namiot A, Sokołowski W. 2010. Calthelicidin LL-37: a multitask antimicrobial peptide. Arch. Immunol. Ther. Exp. 85: 15-25.
17. Liu L, Xu K, Wang H, Tan PK, Fan W, Venkatraman SS, Li L, Yang YY. 2009. Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat. Nanotechnol. 4:457- 463.
18. Guaní-Guerra E, Santos-Mendoza T, Lugo-Reyes SO, Teran LM. 2010. Antimicrobial peptides: general overview and clinical implications in human health and disease. Clin. Immunol. 135:1-11.
19. Wiesner J, Vilcinskas A. 2010. Antimicrobial peptides: the ancient arm of the human immune system. Virulence 1:440-464.
20. Zasloff M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415:389 -395.
21. Yang D, Biragyn A, Kwak LW, Oppenheim JJ. 2002. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol. 23: 291-296.
22. Zaiou M, Nizet V, Gallo RL. 2003. Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37) prosequence. J. Invest. Dermatol. 120:810-816.
23. Alalwani SM, Sierigk J, Herr C, Pinkenburg O, Gallo R, Vogelmeier C, Bals R. 2010. The antimicrobial peptide LL-37 modulates the inflammatory and host defense response of human neutrophils. Eur. J. Immunol. 40:1118 -1126.
24. Izadpanah A, Gallo R. 2005. Antimicrobial peptides. J. Am. Acad. Dermatol. 52:381-390.
25. Lai Y, Gallo RL. 2009. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 30:131-141.
26. Turner J, Cho Y, Dinh N, Waring AJ, Lehrer RI. 1998. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob. Agents Chemother. 42:2206 -2214.
27. Zaiou M. 2007. Multifunctional antimicrobial peptides: therapeutic targets in several human diseases. J. Mol. Med. 85:317-329.
28. Giuliani A, Pirri G, Nicoletto S. 2007. Antimicrobial peptides: an overview of a promising class of therapeutics. Cent. Eur. J. Biol. 2:1-33.
29. Andrès E, Dimarcq JL. 2004. Cationic anti-microbial peptides: from innate immunity study to drug development. J. Rev. Med. 25:629-635.
30. Andrès E, Dimarcq JL. 2004. Cationic antimicrobial peptides: update of clinical development. J. Intern. Med. 255:519 -520.
31. Dimarcq JL. 2003. Developing insect-derived drug candidates. Drug Discov. Today 8:107-110.
32. Hancock RE, Patrzykat A. 2002. Clinical development of cationic antimicrobial peptides: from natural to novel antibiotics. Curr. Drug Targets Infect. Disord. 2:79-83.
33. Yeung TY, Gellatly SL, Hancock REW. 2011. Multifunctional cationic host defence peptides and their clinical applications. Cell. Mol. Life Sci. 68:2161-2176.
34. Welch WD, Jantzen J, Johnson K, Bawdon RE. 1985. Effects of general and local anesthesia on the pharmacokinetics of cefazolin in patients undergoing orthopedic surgery. Antimicrob. Agents Chemother. 27:874-875.
35. Darouiche RO, Hamill RJ. 1994. Antibiotic penetration of and bactericidal activity within endothelial cells. Antimicrob. Agents Chemother. 38: 1059-1064.
36. Tulkens PM. 1991. Intracellular distribution and activity of antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 10:100 -106.
37. Bernardo K, Pakulat N, Fleer S, Schnaith A, Utermohlen O, Krut O, Müller S, Kronke M. 2004. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob. Agents Chemother. 48:546 -555.
38. van den Broek PJ. 1991. Activity of antibiotics against microorganisms ingested by mononuclear phagocytes. Eur. J. Clin. Microbiol. Infect. Dis. 10:114 -118.
39. Ulvatne H, Haukland HH, Samuelsen O, Krämer M, Vorland LH. 2002. Proteases in Escherichia coli and Staphylococcus aureus confer reduced susceptibility to lactoferricin-B. J. Antimicrob. Chemother. 50:461- 467.
40. Yu L, Ding JL, Ho B, Feng S-S, Wohland T. 2008. Investigation of the mechanisms of antimicrobial peptides interacting with membranes by fluorescence correlation spectroscopy. Open Chem. Phys. J. 1:62-79.
41. Hancock RE, Diamond G. 2000. The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol. 8:402- 410.
42. Park SC, Park Y, Hahm KS. 2011. The role of antimicrobial peptides in preventing multidrug-resistant bacterial infections and biofilm formation. Int. J. Mol. Sci. 12:5971-5992.
43. Peschel A, Sahl HS. 2006. The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat. Rev. Microbiol. 4:529 -536.
44. Tossi A, Scocchi M, Zahariev S, Gennaro R. 2012. Use of unnatural amino acids to probe structure activity relationships and mode of action of antimicrobial peptides. Methods Mol. Biol. 794:169 -183.
45. Tossi A, Sandri L, Giangaspero A. 2000. Amphipathic alpha-helical antimicrobial peptides. Biopolymers 55:4 -30.
46. Wu M, Maier E, Benz R, Hancock RE. 1999. Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli. Biochemistry 38: 7235-7242.
47. Scott MG, Hancock RE. 2000. Cationic antimicrobial peptides and their multifunctional role in the immune system. Crit. Rev. Immunol. 20:407- 431.
48. Shai Y. 1999. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell nonselective membrane-lytic peptides. Biochim. Biophys. Acta 1462:55-70.
49. Neville F, Cahuzac M, Nelson A, Gidalevitz D. 2004. The interaction of antimicrobial peptide LL-37 with artificial biomembranes: epifluorescence and impedance spectroscopy approach. J. Phys. Condens. Matter 16:2413-2420.
50. Majerle A, Kidric J, Jerala R. 2003. Enhancement of antibacterial and lipopolysaccharide binding activities of a human lactoferricin peptide fragment by the addition of acyl chain. J. Antimicrob. Chemother. 51: 1159-1165.
51. Porter EA, Weisblum B, Gellman SH. 2002. Mimicry of host-defense peptides by unnatural oligomers: antimicrobial beta-peptides. J. Am. Chem. Soc. 124:7324 -7330.
52. Findlay B, Zhanel GG, Schweizer F. 2010. Cationic amphiphiles, a new generation of antimicrobials inspired by the natural antimicrobial peptide scaffold. Antimicrob. Agents Chemother. 54:4049-4058.
53. Darville T, Jacobs RF. 2004. Management of acute hematogenous osteomyelitis in children. Pediatr. Infect. Dis. J. 23:255-257.
54. Ellington JK, Harris M, Webb L, Smith B, Smith T, Tan K, Hudson M. 2003. Intracellular Staphylococcus aureus: a mechanism for the indolence of osteomyelitis. J. Bone Joint Surg. 85:918 -921.
55. Krogstad P. 2004. Osteomyelitis and septic arthritis, p 713-736. In Feigin RD, Cherry JD, Demmler GJ, Kaplan SL (ed), Textbook of pediatric infectious diseases, 5th ed. Saunders, Philadelphia, PA.
56. Proctor RA, Balwit JM, Vesga O. 1994. Variant subpopulations of Staphylococcus aureus as cause of persistent and recurrent infections. Infect. Agents Dis. 3:302-312.
57. von Eiff C, Becker K, Metze D, Lubritz G, Hockmann J, Schwarz T, Peters G. 2001. Intracellular persistence of Staphylococcus aureus smallcolony variants within keratinocytes: a cause for antibiotic treatment failure in a patient with Darier's disease. Clin. Infect. Dis. 32:1643-1647.
58. Bosse MJ, Gruber HE, Ramp WK. 2005. Internalization of bacteria by osteoblasts in a patient with recurrent, long-term osteomyelitis. A case report. J. Bone Joint Surg. Am. 87:1343-1347.
59. Beck NK, Callahan K, Nappier SP, Kim H, Sobsey MD, Meschkei JS. 2009. Development of a spot-titer culture assay for quantifying bacteria and viral indicators. J. Rapid Methods Autom. Microbiol. 17:455- 464.
60. Herigstad B, Hamilton M, Heersink J. 2001. How to optimize the drop plate method for enumerating bacteria. J. Microbiol. Methods 44:121- 129.
61. Ahmed S, Meghji S, Williams RJ, Henderson B, Brock JH, Nair SP. 2001. Staphylococcus aureus fibronectin binding proteins are essential for internalization by osteoblasts but do not account for differences in intracellular levels of bacteria. Infect. Immun. 69:2872-2877.
62. Ellington JK, Reilly SS, Ramp WK, Smeltzer MS, Kellam JF, Hudson MC. 1999. Mechanisms of Staphylococcus aureus invasion of cultured osteoblasts. Microb. Pathog. 26:317-323.
63. Hamza T, Li B. 2012. Staphylococcus aureus internalization and associated osteoblast responses, paper 0919. Orthopaedic Res. Soc. (ORS) Annu. Meet., 4 to 7 February 2012, San Francisco, CA.
64. Jevon M, Guo C, Ma B, Mordan N, Nair SP, Harris M, Henderson B, Bentley G, Meghji S. 1999. Mechanisms of internalization of Staphylococcus aureus by cultured human osteoblasts. Infect. Immun. 67:2677- 2681.
65. Testoni F, Montanaro L, Poggi A, Visai L, Campoccia D, Arciola CR. 2011. Internalization by osteoblasts of two Staphylococcus aureus clinical isolates differing in their adhesin gene pattern. Int. J. Artif. Organs 34: 789-798.
66. Wu JA, Kusuma C, Mond JJ, Kokai-Kun JF. 2003. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob. Agents Chemother. 47:3407-3414.
67. Armstead AL, Li B. 2011. Nanomedicine as an emerging approach against intracellular pathogens. Int. J. Nanomed. 6:3281-3293.
68. Briones E, Colino CI, Lanao JM. 2008. Delivery systems to increase the selectivity of antibiotics in phagocytic cells. J. Control. Release 125:210 -227.
69. Hudson MC, Ramp WK, Nicholson NC, Williams AS, Nousiainen MT. 1995. Internalization of Staphylococcus aureus by cultured osteoblasts. Microb. Pathog. 19:409-419.
70. Marriott I. 2004. Osteoblast responses to bacterial pathogens-a previously unappreciated role for bone-forming cells in host defense and disease progression. Immunol. Res. 30:291-308.
71. Sendi P, Proctor RA. 2009. Staphylococcus aureus as an intracellular pathogen: the role of small colony variants. Trends Microbiol. 17:54 -58.
72. Sinha B, Fraunholz M. 2010. Staphylococcus aureus host cell invasion and post-invasion events. Int. J. Med. Microbiol. 300:170 -175.
73. Li H, Hamza T, Clovis NB, Smith S, Tidwell J, Li B. 2012. Antimicrobial properties of platelet-rich plasma-in vitro and in vivo studies, paper 0271. Orthopaedic Res. Soc. (ORS) Annu. Meet., 4 to 7 February 2012, San Francisco, CA.
74. Chen X, Niyonsaba F, Ushio H, Okuda D, Nagaoka I, Ikeda S, Okumura K, Ogawa H. 2005. Synergistic effect of antibacterial agents human b-defensins, cathelicidin LL-37 and lysozyme against Staphylococcus aureus and Escherichia coli. J. Dermatol. Sci. 40:123-132.
75. Barańska-Rybak W, Sonesson A, Nowicki R, Schmidtchen A. 2006. Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids. J. Antimicrob. Chemother. 57:260 -265.
76. Hancock RE, Sahl HG. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24:1551-1557.
77. Johansson J, Gudmundsson GH, Rottenberg ME, Berndt KD, Agerberth B. 1998. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J. Biol. Chem. 273:3718 -3724.
78. Ciornei CD, Sigurdardottir T, Schmidtchen A, Bodelsson M. 2005. Antimicrobial and chemoattractant activity, lipopolysaccharide neutralization, cytotoxicity, and inhibition by serum of analogs of human cathelicidin LL-37. Antimicrob. Agents Chemother. 49:2845-2850.
79. Fukumoto K, Nagaoka I, Yamataka A, Kobayashi H, Yanai T, Kato Y, Miyano T. 2005. Effect of antibacterial cathelicidin peptide CAP18/LL-37 on sepsis in neonatal rats. Pediatr. Surg. Int. 21:20 -24.
80. Wang G, Epand RF, Mishra Lushnikova BT, Thomas VC, Kenneth W, Bayles KW, Epand RM. 2012. Decoding the functional roles of cationic side chains of the major antimicrobial region of human cathelicidin LL- 37. Antimicrob. Agents Chemother. 56:845- 856.
81. Boyce BM, Lindsey BA, Clovis NB, Smith ES, Hobbs GR, Hubbard DF, Emery SE, Barnett JB, Li B. 2012. Additive effects of exogenous IL-12 supplementation and antibiotic treatment in infection prophylaxis. J. Orthop. Res. 30:196 -202.
82. Li B, Jiang B, Boyce BM, Lindsey BA. 2009. Multilayer polypeptide nanoscale coatings incorporating IL-12 for the prevention of biomedical device-associated infections. Biomaterials 30:2552-2558.
83. Li B, Jiang B, Dietz MJ, Smith ES, Clovis NB, Rao KM. 2010. Evaluation of local MCP-1 and IL-12 nanocoatings for infection prevention in open fractures. J. Orthop. Res. 28:48 -54.